Asthma Characteristics and Patient-Reported Outcomes in Patients With Atopic Dermatitis in the Rapid Registry of Dupilumab Use in a Real-World Setting

Speaker(s)

Mosnaim GS1, Peters AT2, Lugogo NL3, Price D4, Côté A5, Plaza V6, Xia C7, Gómez LDP8, Kwah J7
1Endeavor Health, Evanston, IL, USA, 2Northwestern University Feinberg School of Medicine, Chicago, IL, USA, 3University of Michigan, Ann Arbor, MI, USA, 4Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore, Singapore, Singapore, 5Quebec Heart and Lung Institute – Laval University, Quebec City, QC, Canada, 6Hospital de la Santa Creu i Sant Pau, Barcelona, Barcelona, Spain, 7Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA, 8Sanofi, Madrid, Madrid, Spain

Presentation Documents

OBJECTIVES: The RAPID registry aims to characterize adults and adolescents with asthma who initiate dupilumab treatment. Dupilumab is a fully human monoclonal antibody that blocks the shared receptor component for interleukin (IL)-4 and IL-13, key drivers of type 2 inflammation in multiple diseases, including asthma and atopic dermatitis (AD). This analysis aims to characterize asthma severity and patient-reported outcomes in patients having asthma with coexisting AD.

METHODS: We report baseline (pre-dupilumab) and/or 12-month asthma severity data by forced expiratory volume in 1 second (FEV1) and exacerbation history, and asthma control using 6-item Asthma Control Questionnaire (ACQ-6) score, in patients with (n=56) and without (n=149) coexisting AD.

RESULTS:

At biologic initiation, 96.6% of patients with a history of AD reported ongoing AD.

At baseline, mean (SD) pre-bronchodilator FEV1 was 2.61 (0.97) L in patients with AD vs 2.17 (0.90) L in those without AD. During the year before screening, ≥1 severe exacerbations were reported by 21/48 (43.8%) patients with AD vs 66/121 (54.5%) patients without AD. Patients with AD had mean (SD) 1.2 (2.0) severe exacerbations, and those without, 2.2 (4.8). During the 12-month treatment period, ≥1 severe exacerbations were experienced by 7/56 (12.5%) of patients with AD and by 12/149 (8.1%) patients without AD; unadjusted annualized rates of severe exacerbation were 0.21 (with AD) and 0.11 (without AD). At baseline, mean (SD) ACQ-6 scores were 2.21 (1.15) (with AD) and 2.40 (1.20) (without AD); at 12 months, 1.06 (0.89) (with AD) and 0.98 (1.12) (without AD).

CONCLUSIONS: Real-world use of dupilumab improves asthma control and reduces exacerbations regardless of coexisting AD. Awareness of such findings in real-world clinical practice may optimize and help improve patient care.

Code

PCR104

Topic

Study Approaches

Topic Subcategory

Clinical Trials

Disease

Biologics & Biosimilars, Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)